Healthcare Industry News: pancreatic ductal adenocarcinoma
News Release - January 8, 2016
Dr. Rolf Muller Appointed as New CEO of BioFluidica, Inc.CHAPEL HILL, N.C., Jan. 8, 2016 -- (Healthcare Sales & Marketing Network) -- BioFluidica, Inc. has announced the appointment of Dr. Rolf Muller as their new Chief Executive Officer. He will assume responsibilities immediately and will succeed Dr. Steven Soper, who will remain the company's Chief Technology Officer.
Dr. Muller, a serial biotech entrepreneur, comes to BioFluidica from Biomatrica, Inc., a company he cofounded. "I am very excited to have the opportunity to advance such powerful liquid biopsy technology in the pursuit of cancer diagnostics. I have worked with Dr. Soper before and look forward to helping BioFluidica develop the next generation diagnostic tests and instruments to help patients worldwide," says Dr. Muller.
Dr. Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. Prior to joining BioFluidica he was the Co-Founder and President of Biomatrica, which he developed from an idea to be a global leader in biopreservation technologies for diagnostic and health care companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to successfully raising capital from investors, he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris, France.
BioFluidica is developing innovative technologies for the isolation and analysis of rare, circulating biomarkers in the blood. The company's first platform has the capacity to isolate circulating tumor cells, exosomes and cfDNA from the blood with unprecedented recovery and purity. The technology is based on patented microfluidics designs and and has been clinically validated for 6 different cancer types including Colorectal Cancer, pancreatic ductal adenocarcinoma, Ovarian Cancer, Breast Cancer, Multiple Myeloma and AML. Additionally, stroke detection and infectious disease identification have also obtained clinical validation using the BioFluidica test. The company was cofounded by Dr. Soper. Dr. Soper is currently a Professor in Biomedical Engineering and Chemistry at the University of North Carolina at Chapel Hill (UNC-CH). He is also Director of a new center on the UNC-CH campus, Center for BioModular Multi-scale Systems for Precision Medicine, focused on developing new tools for the molecular analysis of circulating biomarkers.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.